NIS to examine the effectiveness of TDC in patients with metastatic non-squamous NSCLC and high-risk genetic alterations

Trial Identifier: D419MR00003
Sponsor: AstraZeneca
Start Date: June 2024
Primary Completion Date: June 2028
Study Completion Date: June 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Bad Homburg, Germany
Germany Berlin, Germany
Germany Celle, Germany
Germany Chemnitz, Germany
Germany Georgsmarienhutte, Germany
Germany Goslar, Germany
Germany Halle-Dolau, Germany
Germany Hannover, Germany
Germany Herne, Germany
Germany Koln-Mehrheim, Germany
Germany Munnerstadt, Germany
Germany Neuss, Germany
Germany Ravensburg, Germany
Germany Treuenbrietzen, Germany
Germany Ulm, Germany
Germany Wiesbaden, Germany
Germany Zwickau, Germany